The Future of DNA-Based Inventions: What Have We Learned from Myriad?

June 22, 2015

The Myriad case undoubtedly raised an important debate within the biotech intellectual property community: are natural substances “patent-eligible?” Michele and Eddie co-authored a book chapter entitled “The Impact of Myriad on the Future Development and Commercialization of DNA-based Therapies and Diagnostics.” This comprehensive overview on patent protection in the biotech industry discusses the impact of the Supreme Court ruling on “patent-eligibility” related issues and the controversies of the Revised Guidance published by United States Patent and Trademark Office (USPTO). The book chapter also presents strategies on how to “claim around” in order to fully protect DNA-based inventions.

Read more about the book: http://www.cshlpress.com/default.tpl?cart=1431785593238597905&fromlink=T&linkaction=full&linksortby=oop_title&–eqSKUdatarq=1031

divider line